Table 35.1 Comparison of 2008-2014 5-Year Relative Survivala (Percent) using different Expected Survival Life Tables By Primary Cancer Site, Race and Sex

		All	Races			White				Black			
	Ma	ale	Fem	ale	Ma	le	Fem	ale	Ma	ale	Fem	nale	
Site	USLTb	SES ^c											
All Sites	66.4	66.4	67.5	67.5	66.6	66.5	68.2	68.1	63.7	63.6	59.1	59.1	
Oral Cavity & Pharynx	64.0	64.0	67.0	66.9	65.8	65.8	67.6	67.5	46.0	46.0	52.9	53.0	
Lip	87.6	88.2	89.7	89.3	87.4	88.0	89.9	89.5	66.8	66.8	67.3	67.3	
Tongue	66.2	66.1	64.8	64.8	68.1	68.0	66.1	66.0	42.9	42.9	43.7	43.7	
Salivary gland	64.1	64.0	82.3	82.1	61.9	61.8	81.0	80.8	70.5	70.5	81.8	81.8	
Floor of mouth	51.8	51.9	55.2	55.2	53.0	53.0	57.4	57.3	43.4	43.4	31.3	31.4	
Gum & other oral cavity	55.1	55.2	64.4	64.3	55.2	55.2	63.6	63.5	49.5	49.5	62.4	62.5	
Nasopharynx	59.4	59.4	66.8	66.8	57.1	57.1	62.0	61.9	57.4	57.4	55.0	55.1	
Tonsil	74.6	74.5	70.8	70.9	76.0	75.9	73.2	73.3	57.2	57.2	48.3	48.3	
Oropharynx	47.1	47.1	40.7	40.8	51.0	51.0	42.3	42.4	26.9	27.0	29.0	29.2	
Hypopharynx	32.9	32.9	32.5	32.5	36.1	36.0	34.9	35.0	18.2	18.2	16.8	16.8	
Other oral cavity & pharynx	47.5	47.7	35.4	35.5	51.4	51.6	39.4	39.6	29.0	29.1	16.5	16.5	
Digestive System	41.2	41.2	46.4	46.3	41.6	41.6	47.0	46.8	35.8	35.8	43.3	43.3	
Esophagus	18.9	18.9	20.1	20.0	19.9	19.9	20.3	20.3	11.4	11.4	16.1	16.2	
Stomach	28.4	28.4	35.3	35.1	27.1	27.0	34.5	34.2	26.4	26.4	37.1	37.0	
Small intestine	66.8	66.8	68.5	68.4	67.2	67.2	70.0	69.9	64.1	64.0	63.7	63.8	
Colon & Rectum	64.1	64.1	65.1	64.9	64.7	64.7	65.6	65.4	55.8	55.7	59.8	59.8	
Colon	63.5	63.6	63.7	63.6	64.4	64.4	64.7	64.5	55.2	55.0	56.9	56.9	
Rectum	65.2	65.2	68.7	68.6	65.3	65.3	67.9	67.8	57.3	57.3	68.7	68.7	
Anus, anal canal & anorectum	61.0	60.8	71.5	71.4	62.7	62.5	72.7	72.6	52.8	52.9	63.4	63.4	
Liver & intrahepatic	17.5	17.5	18.4	18.4	17.0	16.9	17.5	17.5	13.3	13.3	16.2	16.2	
bile duct													
Gallbladder	18.4	18.4	18.2	18.1	17.8	17.7	18.4	18.3	15.2	15.3	16.9	17.0	
Other biliary	18.9	18.8	16.1	16.1	19.6	19.5	15.3	15.3	11.0	11.0	16.0	16.0	
Pancreas	8.8	8.8	8.3	8.3	8.8	8.7	8.1	8.0	7.6	7.6	9.5	9.5	
Retroperitoneum	53.0	52.9	55.5	55.4	52.8	52.6	54.5	54.4	59.2	58.9	52.9	52.9	
Peritoneum, omentum & mesentery	38.4	38.2	31.5	31.5	37.1	36.9	31.1	31.0	34.1	33.8	26.5	26.5	
Other digestive system	7.1	7.1	10.2	10.2	7.1	7.0	10.7	10.6	6.0	6.0	6.4	6.4	

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, lowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2015.

Expected survival rates are derived from the U.S. Annual Life Tables.

Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program. For more information on the life tables, see: https://seer.cancer.gov/expsurvival/.

Table 35.1 Comparison of 2008-2014 5-Year Relative Survivala (Percent) using different Expected Survival Life Tables By Primary Cancer Site, Race and Sex

		All F	Races			White				Black			
	Ma	ale	Fem	nale	Ma	le	Fem	ale	Male		Fem	Female	
Site	USLTb	SES ^c	USLT ^b	SES ^c	USLTb	SES ^c							
Respiratory System	20.1	20.2	23.2	23.3	20.4	20.4	23.3	23.3	17.7	17.7	21.3	21.3	
Nose, nasal cavity & middle ear	59.1	59.2	56.7	56.6	62.1	62.2	57.5	57.4	44.0	44.1	56.6	56.6	
Larynx	61.3	61.4	58.3	58.4	62.6	62.7	59.5	59.6	52.5	52.5	49.8	50.0	
Lung & bronchus	15.4	15.5	21.9	22.0	15.6	15.7	22.0	22.0	13.2	13.2	19.8	19.8	
Pleura	24.6	24.7	28.4	28.3	24.9	25.0	14.1	14.1	-	_	58.5	58.6	
Trachea & other respiratory organs	53.6	53.6	52.2	52.2	53.7	53.7	53.0	53.0	46.6	46.8	42.7	42.8	
Bones & joints	65.1	65.1	69.3	69.2	64.8	64.8	69.5	69.4	66.0	66.0	64.2	64.2	
Soft tissue (including heart)	63.8	63.8	65.4	65.3	64.4	64.3	66.2	66.1	59.7	59.7	59.8	59.8	
Skin (excl. basal & squamous)	89.3	89.3	93.8	93.6	88.5	88.5	93.3	93.2	77.2	77.2	84.6	84.6	
Melanoma of the skin	89.9	89.9	94.3	94.2	89.2	89.2	93.9	93.8	57.3	57.1	71.0	71.0	
Other non-epithelial skin	82.6	82.5	87.0	86.7	80.2	80.1	84.5	84.1	90.5	90.6	95.4	95.4	
Breast	83.2	83.0	89.8	89.7	85.2	84.9	90.8	90.6	70.8	70.9	81.1	81.2	
Breast (in situ)	_	-	69.4	69.3	=	-	70.8	70.7	-	-	55.6	55.7	
Female Genital System	-	-	66.3	66.2	-		67.9	67.7	-	-	55.5	55.5	
Cervix uteri	-	_	81.2	81.1	_	-	83.5	83.4	-	_	61.5	61.6	
Corpus uteri	-	_	82.6	82.5	-	-	84.7	84.6	-	-	63.9	64.0	
Uterus, NOS	-	_	29.7	29.6	_	-	32.7	32.5	-	_	20.6	20.6	
Ovary	-	_	47.4	47.4	_	-	47.4	47.4	-	_	38.5	38.5	
Vagina	-	_	47.0	47.0	-	-	47.2	47.2	-	-	44.9	45.0	
Vulva	-	_	71.1	71.0	_	-	70.5	70.4	-	_	71.9	71.8	
Other female genital system	-	-	53.6	53.6	-		52.4	52.4	-	-	56.2	56.2	
Male Genital System	98.0	97.9	-	=	98.1	98.0	_	_	96.0	95.9	_	_	
Prostate	98.3	98.2	_	_	98.4	98.3	_	_	96.2	96.1	_	_	
Testis	95.4	95.3	_	-	95.5	95.4	-	_	91.6	91.8	_	-	
Penis	67.2	67.2	_	_	67.1	67.0	_	_	58.7	58.4	_	_	
Other male genital system	85.0	84.9	_	_	86.5	86.2	=	-	63.6	63.4	-	-	
Urinary System	75.8	75.9	73.9	73.8	76.1	76.1	74.5	74.4	71.3	71.1	68.5	68.6	
Urinary bladder	78.0	78.1	73.1	72.9	78.3	78.3	74.3	74.1	67.5	67.1	55.1	55.0	
Kidney & renal pelvis	73.7	73.7	75.8	75.8	73.7	73.6	75.8	75.8	74.2	74.2	76.1	76.3	
Ureter	48.1	48.3	45.6	45.4	48.7	48.8	47.6	47.4	28.2	28.1	33.4	33.4	
Other urinary system	54.0	54.2	37.9	37.7	53.3	53.5	40.2	39.9	44.8	44.8	17.9	18.0	

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, lowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2015.

Expected survival rates are derived from the U.S. Annual Life Tables.

Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program. For more information on the life tables, see: https://seer.cancer.gov/expsurvival/.

Table 35.1 Comparison of 2008-2014 5-Year Relative Survivala (Percent) using different Expected Survival Life Tables By Primary Cancer Site, Race and Sex

		All	l Races			White				Black			
	M	ale	Fe	male	Ma	ıle	Fe	male	Ma	le	Fe	emale	
Site	USLTb	SES ^c	USLT ^b	SESc	USLT ^b	SES ^c	USLTb	SES ^c	USLTb	SES ^c	USLT	SES ^c	
Eye & Orbit	82.3	82.4	83.5	83.6	81.3	81.4	82.7	82.8	86.4	86.3	93.2	93.2	
Brain & Nervous System	32.0	32.0	34.8	34.7	30.8	30.7	33.7	33.6	38.1	38.1	40.9	40.9	
Brain	29.4	29.4	31.1	31.1	28.3	28.2	30.0	30.0	34.9	35.0	36.6	36.6	
Cranial nerves & other nervous system	75.7	75.6	82.1	82.0	76.4	76.3	83.7	83.6	74.1	74.2	75.7	75.7	
Endocrine System	92.2	92.1	97.8	97.7	92.8	92.7	98.1	98.0	85.5	85.5	95.8	96.0	
Thyroid	95.7	95.6	98.9	98.8	96.0	95.8	99.0	99.0	92.9	92.9	97.7	97.7	
Other endocrine & thymus	64.6	64.5	64.5	64.4	64.0	63.9	63.3	63.1	63.0	63.1	67.1	67.1	
Lymphoma	72.1	72.0	75.4	75.3	72.4	72.3	75.6	75.5	66.7	66.7	73.1	73.2	
Hodgkin lymphoma	85.8	85.7	87.8	87.7	86.3	86.2	87.8	87.7	80.3	80.4	87.8	87.8	
Non-Hodgkin lymphoma	69.9	69.9	73.4	73.3	70.3	70.2	73.8	73.6	63.4	63.3	69.6	69.6	
Myeloma	50.7	50.6	50.9	50.9	50.2	50.1	49.9	49.8	51.5	51.3	52.8	52.8	
Leukemia	62.5	62.5	60.1	60.0	62.7	62.7	60.7	60.6	57.0	56.9	53.7	53.6	
Lymphocytic	80.3	80.3	78.9	78.8	80.4	80.4	79.3	79.3	72.3	72.1	67.5	67.4	
Acute lymphocytic	67.8	67.8	68.6	68.5	67.6	67.5	69.1	69.1	66.0	66.0	60.2	60.2	
Chronic lymphocytic	84.4	84.4	83.9	83.8	84.4	84.4	83.9	83.9	74.6	74.3	71.5	71.2	
Other lymphocytic	85.2	85.0	70.2	70.2	85.9	85.7	71.6	71.6	71.0	70.7	49.3	49.2	
Myeloid & Monocytic	40.2	40.1	40.8	40.7	39.1	39.1	39.9	39.9	42.7	42.7	44.7	44.8	
Acute myeloid	26.4	26.3	28.6	28.6	25.9	25.9	28.0	28.0	26.5	26.5	30.9	30.9	
Chronic myeloid	66.4	66.4	69.3	69.3	65.4	65.4	68.0	68.0	67.8	67.8	72.2	72.3	
Acute monocytic	21.3	21.3	25.4	25.4	21.7	21.7	26.4	26.4	21.1	21.1	28.4	28.4	
Other myeloid & monocytic	36.8	36.7	31.3	31.5	32.6	32.6	31.0	31.2	49.1	48.8	28.1	28.2	
Other leukemia	33.2	33.2	34.5	34.5	32.3	32.3	35.2	35.1	36.5	36.4	33.3	33.3	
Other acute leukemia	23.5	23.5	23.4	23.4	23.9	23.8	22.9	22.8	18.1	18.0	27.0	27.1	
Aleukemic, subleukemic & NOS	40.6	40.6	42.1	42.1	39.2	39.2	44.3	44.2	45.1	45.0	35.1	35.1	
Miscellaneous	21.6	21.6	14.8	14.8	22.9	22.9	14.8	14.8	12.5	12.5	14.1	14.1	
Kaposi Sarcoma	74.2	73.9	74.9	73.5	76.7	76.3	82.7	81.7	65.4	65.4	33.8	33.8	
Mesothelioma	7.0	7.0	16.6	16.6	7.0	7.0	15.9	15.9	7.0	7.0	25.8	25.8	
Ill-defined & unspecified	100.0	100.0	100.0	100.0	100.0	99.9	100.0	100.0	78.3	78.3	100.0	100.0	

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, lowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2015.

Expected survival rates are derived from the U.S. Annual Life Tables.

Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program. For more information on the life tables, see: https://seer.cancer.gov/expsurvival/.

Table 35.2 Comparison of 2014 Period Survivala (Percent) using different Expected Survival Life Tables By Primary Cancer Site, Race and Sex

			Ma	ale			Female						
	All R		Whi		Bla		All R		Whi		Bla		
Site	USLTb	SES ^c	USLT ^b	SES ^c									
All Sites	65.7	65.7	65.7	65.7	63.1	63.0	68.0	67.9	68.6	68.5	59.7	59.7	
Oral Cavity & Pharynx	64.4	64.4	66.0	66.0	47.2	47.2	67.6	67.6	68.3	68.2	54.4	54.4	
Esophagus	19.9	19.9	20.8	20.8	12.0	12.0	23.0	22.9	24.0	23.9	16.1	16.1	
Stomach	28.9	28.8	27.8	27.6	26.1	26.0	36.8	36.6	36.2	35.9	40.0	39.9	
Colon & Rectum	63.5	63.5	64.0	64.0	55.8	55.7	64.9	64.8	65.4	65.2	60.0	60.0	
Liver & Intrahepatic Bile Duct	17.6	17.6	17.1	17.0	14.0	14.0	18.8	18.7	17.9	17.8	16.5	16.6	
Pancreas	9.5	9.5	9.4	9.4	8.4	8.4	9.4	9.3	9.0	9.0	10.9	10.9	
Larynx	60.4	60.5	61.8	61.9	50.7	50.8	59.8	60.0	61.2	61.3	51.8	51.9	
Lung & Bronchus	15.6	15.7	15.7	15.8	13.3	13.3	22.7	22.7	22.7	22.7	20.3	20.3	
Melanoma of the Skin	90.0	89.9	89.1	89.0	57.1	56.9	94.5	94.4	94.1	94.0	67.5	67.5	
Breast	_	-	_	-	-	-	89.9	89.9	90.8	90.7	81.6	81.6	
Cervix	_	-	=	-	-	-	54.7	54.5	55.6	55.4	44.7	44.7	
Corpus & Uterus, NOS	-	-	-	-	-	-	80.0	79.9	82.5	82.4	59.3	59.4	
Ovary	-	-	-	-	-	-	31.5	31.5	32.1	32.1	21.3	21.3	
Prostate	98.7	98.4	98.9	98.5	97.5	97.4	-	_	-	-	-	-	
Urinary Bladder	77.8	77.9	78.1	78.1	66.0	65.5	72.4	72.3	73.4	73.3	55.5	55.4	
Kidney & Renal Pelvis	74.1	74.1	73.9	73.9	75.3	75.3	76.4	76.4	76.3	76.3	78.0	78.2	
Hodgkin Lymphoma	85.9	85.8	86.3	86.2	81.1	81.2	87.9	87.8	87.9	87.7	87.5	87.5	
Non-Hodgkin Lymphoma	70.1	70.0	70.3	70.2	65.1	65.0	73.9	73.7	74.1	74.0	71.4	71.4	
Myeloma	51.3	51.2	50.7	50.6	52.2	52.0	52.2	52.1	51.2	51.0	52.9	52.9	
Leukemia	63.3	63.3	63.3	63.3	58.2	58.1	60.0	60.0	60.7	60.7	52.1	52.0	
Acute Lymphocytic Leuk	68.9	68.9	68.5	68.5	64.3	64.3	68.5	68.5	69.0	68.9	59.9	60.0	

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Georgia excluding ATL/RG).

Period survival provides a 2014 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2012-2014: 0-1 year survival), (2011-2013: 1-2 year survival), (2010-2012: 2-3 year survival), (2009-2011: 3-4 year survival), (2008-2010: 4-5 years survival). Based on follow-up of patients into 2015.

Expected survival rates are derived from the U.S. Annual Life Tables from the National Center for Health Statistics (NCHS). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

b

Table 35.3 Comparison of 5-Year Relative Survivala (Percent) using different Expected Rate Tables By Primary Cancer Site, Race, and Age Males, 2008-2014

	White							Black						
	Ages			65-74		75+	Ages			65-74		75+		
Site	USLT ^b	SES ^c												
All Sites	71.4	71.2	68.7	68.9	53.0	53.0	65.6	65.6	66.3	66.3	49.3	48.4		
Oral Cavity & Pharynx	70.4	70.2	60.8	61.1	51.0	51.2	48.9	49.0	39.8	39.9	25.6	25.2		
Esophagus	21.5	21.4	22.6	22.7	12.5	12.5	10.6	10.6	13.0	13.0	11.0	11.0		
Stomach	29.7	29.6	29.0	29.0	20.7	20.3	29.9	29.9	24.6	24.5	18.6	18.3		
Colon & Rectum	68.3	68.1	66.3	66.7	56.0	56.1	58.9	59.0	55.1	55.2	43.4	42.4		
Liver & Intrahepatic Bile Duct	20.1	20.0	13.6	13.5	7.7	7.6	13.7	13.7	13.8	13.7	5.7	5.5		
Pancreas	11.6	11.6	8.4	8.5	4.8	4.8	9.8	9.8	5.0	5.0	3.1	3.0		
Larynx	63.9	63.9	61.2	61.7	61.2	61.1	52.8	52.9	53.8	53.9	45.7	45.2		
Lung & Bronchus	17.5	17.5	16.7	16.9	11.9	12.0	14.9	14.9	13.1	13.1	8.3	8.1		
Melanoma of the Skin	90.2	90.0	90.3	90.7	84.2	84.4	61.6	61.6	49.9	49.6	41.5	41.2		
Prostate	99.1	98.8	100.0	100.0	92.2	92.1	97.6	97.6	97.1	97.1	86.5	85.2		
Urinary Bladder	83.9	83.7	80.6	81.0	70.9	70.9	70.8	70.8	66.8	66.9	61.7	59.9		
Kidney & Renal Pelvis	78.1	77.9	72.2	72.5	60.0	59.8	76.3	76.4	73.1	73.2	59.0	57.9		
Hodgkin Lymphoma	91.2	91.1	64.2	64.4	47.4	47.2	80.7	80.8	74.2	74.4	-	-		
Non-Hodgkin Lymphoma	78.2	78.0	70.0	70.2	52.4	52.3	65.4	65.4	63.1	63.0	44.0	43.2		
Myeloma	62.5	62.2	50.0	50.1	30.3	30.1	57.2	57.3	50.9	50.8	33.1	32.1		
Leukemia	73.1	73.0	59.1	59.3	42.5	42.5	62.8	62.9	52.1	52.1	35.4	34.5		
Acute Lymphocytic Leuk	71.9	71.9	20.2	20.1	11.1	11.0	68.3	68.3	-	-	-	-		

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Based on follow-up of patients into 2015
Expected survival rates are derived from the U.S. Annual Life Tables.
Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.
For more information on the life tables, see: https://seer.cancer.gov/expsurvival/.

Table 35.3 cont. Comparison of 5-Year Relative Survivala (Percent) using different Expected Rate Tables By Primary Cancer Site, Race, and Age Females, 2008-2014

	White						Black						
	Ages	<65		65-74		75+	Ages	<65	Ages	65-74		75+	
Site	USLTb	SES ^c	USLT ^b	SES ^c									
All Sites	78.3	78.2	64.8	65.0	49.6	49.2	66.3	66.4	54.8	55.1	39.5	38.9	
Oral Cavity & Pharynx	75.9	75.9	66.0	66.1	50.9	50.5	55.7	55.8	54.8	55.2	35.3	35.0	
Esophagus	26.0	25.9	26.7	26.7	11.2	11.1	17.4	17.5	16.5	16.6	10.6	10.5	
Stomach	39.4	39.4	39.3	39.2	26.2	25.6	43.2	43.3	41.8	41.9	24.9	24.5	
Colon & Rectum	71.6	71.5	68.4	68.5	57.7	57.2	64.6	64.8	62.9	63.3	46.6	45.9	
Liver & Intrahepatic Bile Duct	26.8	26.8	14.8	14.8	6.2	6.1	20.0	20.1	13.0	13.0	6.8	6.7	
Pancreas	14.8	14.8	7.4	7.5	3.6	3.5	15.7	15.7	6.9	7.0	3.8	3.8	
Larynx	65.9	66.0	53.8	54.1	47.2	47.0	50.2	50.4	44.6	45.0	55.3	54.9	
Lung & Bronchus	25.9	26.0	24.1	24.2	16.4	16.3	23.0	23.1	19.5	19.6	14.2	14.0	
Melanoma of the Skin	95.7	95.6	94.2	94.4	85.4	85.0	79.3	79.4	64.5	64.8	49.9	49.2	
Breast	91.2	91.1	92.2	92.4	87.6	87.0	81.3	81.4	84.1	84.6	75.6	74.5	
Cervix	72.1	72.0	52.3	52.3	36.4	35.7	58.9	59.0	50.3	50.6	31.6	31.0	
Corpus & Uterus, NOS	87.5	87.4	81.1	81.1	70.8	70.1	68.0	68.1	56.8	57.1	41.2	40.8	
Ovary	60.7	60.6	40.6	40.6	21.9	21.8	49.9	50.0	28.0	28.2	11.1	10.9	
Urinary Bladder	83.1	83.2	77.6	77.8	65.7	65.1	60.6	60.8	61.2	61.6	46.0	45.2	
Kidney & Renal Pelvis	83.7	83.6	75.7	75.9	58.1	57.8	81.7	81.9	73.0	73.5	60.0	59.5	
Hodgkin Lymphoma	92.9	92.8	70.8	70.9	48.6	47.9	90.9	91.0	56.4	56.2	38.3	38.1	
Non-Hodgkin Lymphoma	84.5	84.5	74.9	75.0	57.8	57.4	75.1	75.2	68.7	69.1	50.3	49.6	
Myeloma	64.5	64.4	52.4	52.4	31.7	31.4	64.6	64.7	49.1	49.4	31.6	31.2	
Leukemia	73.1	73.0	60.0	60.1	41.2	41.1	62.0	62.1	51.9	52.2	31.4	30.7	
Acute Lymphocytic Leuk	74.4	74.4	22.2	22.1	9.9	9.8	66.3	66.4	_	-	-	-	

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Based on follow-up of patients into 2015
Expected survival rates are derived from the U.S. Annual Life Tables.
Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.
For more information on the life tables, see: https://seer.cancer.gov/expsurvival/.

Table 35.4 Comparison of 5-Year Relative Survivala (Percent) using different Expected Rate Tables By Primary Cancer Site and Stage at Diagnosis White Males, 2008-2014

	Stage at Diagnosis								
		lized		onal	Distant		Unstaged		
Site	USLT ^b	SES ^c	USLT ^b	SES ^c	USLT ^b SE	S ^c USLT	b SES ^c		
All Sites	90.5	90.4	62.0	62.0	26.8 26.	7 36.0	35.8		
Oral Cavity & Pharynx	82.9	83.0	68.1	68.0	40.4 40.	4 46.4	46.4		
Esophagus	50.0	50.1	23.7	23.7	4.6 4.	6 12.0	12.0		
Stomach	63.5	63.3	28.9	28.8	5.5 5.	4 18.5	18.3		
Colon & Rectum	89.1	89.2	71.8	71.8	13.4 13.	4 35.2	35.1		
Liver & Intrahepatic Bile Duct	30.0	29.9	10.4	10.4	2.2 2.	1 5.3	5.2		
Pancreas	37.1	37.0	12.4	12.4	2.7 2.	7 6.0	6.0		
Larynx	78.3	78.5	45.4	45.4	33.8 33.	8 57.3	57.2		
Lung & Bronchus	50.2	50.5	26.1	26.2	3.7 3.	7 6.4	6.4		
Melanoma of the Skin	97.4	97.3	61.3	61.3	21.1 21.	1 80.1	80.3		
Prostate	100.0	100.0	100.0	99.8	32.9 32.	7 88.4	88.0		
Urinary Bladder	71.7	71.7	37.2	37.2	4.9 4.	8 48.1	48.0		
Kidney & Renal Pelvis	92.6	92.5	70.4	70.4	11.8 11.	8 37.0	37.0		
Hodgkin Lymphoma	92.9	92.8	92.5	92.4	79.3 79.	2 78.7	78.6		
Non-Hodgkin Lymphoma	82.8	82.7	75.4	75.3	63.3 63.	2 64.7	64.5		
Myeloma	74.0	73.8	-	=	48.7 48.	6 –	-		
Leukemia	49.5	49.5	-	_	62.7 62.	7 -	-		
Acute Lymphocytic Leuk	-	-	-	_	67.6 67.	5 –	-		

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Based on follow-up of patients into 2015
Expected survival rates are derived from the U.S. Annual Life Tables.
Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.
For more information on the life tables, see: https://seer.cancer.gov/expsurvival/.

Table 35.4 cont. Comparison of 5-Year Relative Survivala (Percent) using different Expected Rate Tables By Primary Cancer Site and Stage at Diagnosis White Females, 2008-2014

	Stage at Diagnosis										
	Local		Regio		Dist			Unstaged			
Site	USLT ^b	SES ^c	USLTb	SES ^c	USLT ^b	SES ^c	USLT ^b	SES ^c			
All Sites	91.6	91.4	69.4	69.3	26.7	26.7	28.4	28.3			
Oral Cavity & Pharynx	84.7	84.5	61.7	61.7	38.0	38.0	48.6	48.5			
Esophagus	37.4	37.4	26.2	26.2	7.3	7.3	10.9	10.8			
Stomach	72.0	71.4	30.2	29.9	4.2	4.2	27.2	26.9			
Colon & Rectum	91.1	90.9	71.9	71.7	15.4	15.4	29.0	28.8			
Liver & Intrahepatic Bile Duct	30.8	30.6	11.9	11.9	4.0	3.9	6.0	5.9			
Pancreas	31.8	31.7	10.6	10.6	2.6	2.6	3.8	3.7			
Larynx	75.0	75.2	48.1	48.2	33.9	33.9	53.0	52.8			
Lung & Bronchus	61.3	61.3	33.2	33.3	5.5	5.5	7.6	7.6			
Melanoma of the Skin	98.9	98.8	68.2	68.1	24.7	24.7	85.1	85.1			
Breast	99.7	99.6	85.9	85.8	25.2	25.2	47.9	47.6			
Cervix	87.7	87.4	51.9	51.7	16.7	16.6	33.1	32.9			
Corpus & Uterus, NOS	95.8	95.7	70.1	69.9	15.7	15.6	43.9	43.8			
Ovary	87.2	87.3	60.2	60.2	21.3	21.3	10.8	10.8			
Urinary Bladder	63.3	63.1	31.4	31.3	4.5	4.4	34.2	34.1			
Kidney & Renal Pelvis	93.3	93.3	66.8	66.7	11.7	11.6	34.1	33.9			
Hodgkin Lymphoma	91.3	91.3	94.5	94.4	77.2	77.0	85.6	85.4			
Non-Hodgkin Lymphoma	84.3	84.2	75.8	75.7	67.4	67.3	70.8	70.4			
Myeloma	70.6	70.6	-	_	48.9	48.8	-	-			
Leukemia	48.8	48.9	-	-	60.7	60.7	-	-			
Acute Lymphocytic Leuk	_	-	-	_	69.1	69.1	-	-			

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Based on follow-up of patients into 2015
Expected survival rates are derived from the U.S. Annual Life Tables.
Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.
For more information on the life tables, see: https://seer.cancer.gov/expsurvival/.

Table 35.4 cont. Comparison of 5-Year Relative Survivala (Percent) using different Expected Rate Tables By Primary Cancer Site and Stage at Diagnosis Black Males, 2008-2014

	Stage at Diagnosis										
	Loca	lized	Reg	ional	Dist		Unst				
<u>Site</u>	USLT ^b	SES ^c	USLT ^b	SES ^c	USLT ^b	SES ^c	USLT ^b	SES ^c			
All Sites	91.0	90.9	56.5	56.4	21.9	21.8	33.5	33.3			
Oral Cavity & Pharynx	75.7	75.7	48.0	48.0	28.9	28.9	44.9	44.9			
Esophagus	26.0	26.1	17.3	17.3	1.9	1.9	10.3	10.3			
Stomach	58.3	58.2	31.1	31.1	4.9	4.9	13.9	13.8			
Colon & Rectum	85.0	84.8	62.7	62.6	9.5	9.5	39.1	38.9			
Liver & Intrahepatic Bile Duct	24.5	24.4	7.1	7.1	1.1	1.1	8.9	8.9			
Pancreas	26.0	25.9	12.8	12.8	2.4	2.4	9.2	9.2			
Larynx	72.6	72.6	39.2	39.3	31.0	31.1	30.9	30.8			
Lung & Bronchus	44.7	44.6	23.7	23.7	3.9	3.9	8.4	8.3			
Melanoma of the Skin	87.5	87.2	36.5	36.4	13.4	13.5	-	-			
Prostate	100.0	100.0	100.0	100.0	33.3	33.3	85.1	84.8			
Urinary Bladder	63.4	63.0	23.8	23.7	4.6	4.6	48.6	48.2			
Kidney & Renal Pelvis	91.8	91.8	61.4	61.4	7.4	7.4	51.6	51.5			
Hodgkin Lymphoma	92.0	92.2	91.2	91.4	71.4	71.4	73.2	73.1			
Non-Hodgkin Lymphoma	76.0	76.0	71.8	71.8	55.4	55.3	60.8	60.7			
Myeloma	70.4	70.4	-	_	50.6	50.4	-	-			
Leukemia	-	_	-	_	56.9	56.9	-	_			
Acute Lymphocytic Leuk	-	_	-	-	66.0	66.0	-	-			

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Based on follow-up of patients into 2015
Expected survival rates are derived from the U.S. Annual Life Tables.
Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.
For more information on the life tables, see: https://seer.cancer.gov/expsurvival/.

Table 35.4 cont. Comparison of 5-Year Relative Survivala (Percent) using different Expected Rate Tables By Primary Cancer Site and Stage at Diagnosis Black Females, 2008-2014

	Stage at Diagnosis									
	Local		Regio		Dist			Unstaged		
Site	USLT ^b	SES ^c	USLTb	SES ^c	USLT ^b	SES ^c	USLT ^b	SES ^c		
All Sites	86.9	87.0	61.0	61.1	22.5	22.5	28.5	28.5		
Oral Cavity & Pharynx	84.0	84.1	46.7	46.8	29.3	29.3	33.4	33.3		
Esophagus	25.6	25.7	20.9	20.9	7.3	7.4	12.3	12.3		
Stomach	72.9	72.7	31.0	30.9	8.4	8.4	27.2	27.1		
Colon & Rectum	87.9	87.9	67.5	67.6	11.3	11.3	36.8	36.6		
Liver & Intrahepatic Bile Duct	30.0	30.0	8.9	8.9	0.0	0.0	6.7	6.7		
Pancreas	34.1	34.1	11.4	11.4	3.4	3.4	8.5	8.5		
Larynx	65.3	65.4	48.7	48.9	31.5	31.6	-	_		
Lung & Bronchus	59.0	59.1	31.0	31.1	5.6	5.6	12.8	12.7		
Melanoma of the Skin	84.3	84.3	55.8	56.0	39.8	39.8	-	-		
Breast	95.8	95.9	75.9	76.0	17.0	17.0	43.9	43.5		
Cervix	82.5	82.7	46.6	46.6	11.2	11.2	27.3	27.2		
Corpus & Uterus, NOS	84.0	84.1	45.9	46.0	7.8	7.8	36.6	36.5		
Ovary	72.2	72.1	41.2	41.1	13.3	13.4	9.4	9.3		
Urinary Bladder	49.8	49.6	31.6	31.7	1.4	1.4	19.0	19.0		
Kidney & Renal Pelvis	89.9	90.1	63.4	63.6	13.1	13.2	38.3	38.2		
Hodgkin Lymphoma	91.8	91.8	92.8	92.9	83.0	83.1	-	_		
Non-Hodgkin Lymphoma	84.1	84.1	69.2	69.2	60.5	60.6	67.0	66.9		
Myeloma	60.7	60.8	-	-	52.6	52.6	-	-		
Leukemia	-	-	-	-	53.6	53.6	-	-		
Acute Lymphocytic Leuk	-	-	-	-	60.2	60.2	-	=		

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Based on follow-up of patients into 2015
Expected survival rates are derived from the U.S. Annual Life Tables.
Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.
For more information on the life tables, see: https://seer.cancer.gov/expsurvival/.